SMALL CELL LUNG CANCER

This early-phase study tested two drugs, tarlatamab and AMG 404, together in 23 adults with small cell lung cancer that had worsened after standard chemotherapy. The main goal was to check safety and find the right dose for future studies. While the treatment aims to control the …

This early-stage study tested a new drug called SNB-101 in 21 people with advanced solid tumors (like colorectal, breast, or lung cancer) that had stopped responding to standard treatments. The drug is a nanoparticle version of a chemotherapy agent, given through an IV, and the m…

This early-stage study tested a new drug called CTX-471, given alone or with another immunotherapy (pembrolizumab), in 100 adults with advanced cancers like lung cancer, melanoma, or head and neck cancer that had stopped responding to standard PD-1/PD-L1 inhibitors. The main goal…

This study tested a pill called abemaciclib in 14 people with advanced lung cancers (small cell, large cell neuroendocrine, and related types) that had stopped responding to chemotherapy. The goal was to see if the drug could shrink tumors and how safe it was. Participants took t…

This study tested a combination of two drugs, anlotinib and penpulimab, in 65 people with small cell lung cancer whose disease had worsened after first-line platinum chemotherapy. The goal was to see if the combination could shrink tumors or slow cancer growth. Participants recei…

This study tested a combination of two drugs, NT-I7 and pembrolizumab, in 215 people with advanced solid tumors that had come back or stopped responding to treatment. The goal was to find a safe dose and see if the combo could shrink tumors. The study included people with several…

This study tested whether adding the experimental drug tiragolumab to standard chemotherapy and immunotherapy could help people with advanced small cell lung cancer live longer without their cancer growing. About 490 adults who had not received prior treatment for this aggressive…

This study looked at 45 people with limited-stage small-cell lung cancer who received the immunotherapy drug durvalumab after standard chemoradiation. Researchers measured how long patients lived without their cancer getting worse. The goal was to see if adding durvalumab helps c…

This study tested whether adding the drug trilaciclib to standard chemotherapy and immunotherapy could protect bone marrow and the immune system in people with advanced small cell lung cancer. About 100 participants received either trilaciclib or a placebo alongside their cancer …

This study tested a special nursing program for 200 people with advanced small cell lung cancer receiving chemotherapy plus immunotherapy. The program used a team of nurses, dietitians, and mental health experts to monitor side effects, support medication adherence, and provide n…

This study tested a drug called trilaciclib in 123 people with advanced small cell lung cancer who were getting chemotherapy. The goal was to see if it could protect their bone marrow and immune system from damage caused by chemo, reducing side effects like low white blood cell c…

This study looked at whether a blood test that detects tumor DNA could help monitor lung cancer progression without needing a biopsy. Researchers tested 200 patients with non-small cell or small cell lung cancer. The goal was to see if this non-invasive method could track how the…

This study looked at whether a new type of PET/CT scan can help predict how well treatment will work for people with a certain type of lung cancer (limited-stage small cell lung cancer). 33 patients had this special scan before starting standard treatment. The goal was to see if …